| Name | Title | Contact Details |
|---|
ChoiceSpine, LP was founded in December of 2006 in Knoxville, TN. The company is designed to take to the market technically-superior spinal products through a service-focused distribution network. The management team of ChoiceSpine has more than 70 years of industry experience in the areas of research and development, engineering and manufacturing, distribution and sales, financial management and administration. Rick Henson and Marty Altshuler are co-founders and executives of the corporation. They have extensive knowledge of the orthopedic and spinal markets. They are co-principals of ChoiceSpine. They have worked together for 20 years in creating successful healthcare businesses. ChoiceSpine acquired Orthotec, a 40 million dollar company, and now holds the exclusive rights for the U.S. market, several patents and 6 specific spinal conditions. These innovative and proprietary products, when combined with effective procedures, have a successful track record of producing better quality outcomes in surgical patients.
St Lawrence Medical Association is a Reading, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Riverain Technologies is dedicated to thoracic imaging, providing software tools to aid clinicians in the efficient, effective early detection of lung disease. With Riverain`s ClearRead applications, clinicians are empowered by tools that enable them to read faster and more effectively across the entire enterprise.
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.
Procyrion is developing the first catheter-deployed circulatory assist device intended for long-term use. The Procyrion device will be the first minimally invasive tool for cardiologists to treat over 1M NYHA Class III and early class IV heart failure (HF) patients in the US who have few therapeutic options. In partnership with Texas Heart Institute, Procyrion is currently conducting preclinical testing of the Procyrion device.